In one paragraphArticle in Circulation. Genomic and precision medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
24 authors.
Frits I Mulder *Department of Vascular Medicine, Amsterdam UMC Location University of Amsterdam, the Netherlands (F.I.M., N.A.M.G., R.J.v.G., T.F.v.H., V.H., H.R.B., P.W.K., N.v.E.).ORCID 0000-0002-6902-3425 Noori A M Guman *Department of Vascular Medicine, Amsterdam UMC Location University of Amsterdam, the Netherlands (F.I.M., N.A.M.G., R.J.v.G., T.F.v.H., V.H., H.R.B., P.W.K., N.v.E.).ORCID 0000-0003-1426-3170 Job van RietDivision of AI in Oncology, German Cancer Research Ctr DKFZ, Heidelberg, Germany (J.v.R.).ORCID 0000-0001-7767-7923 Roos J van GeffenDepartment of Vascular Medicine, Amsterdam UMC Location University of Amsterdam, the Netherlands (F.I.M., N.A.M.G., R.J.v.G., T.F.v.H., V.H., H.R.B., P.W.K., N.v.E.).ORCID 0000-0003-1818-3928 Thijs F van HaapsDepartment of Vascular Medicine, Amsterdam UMC Location University of Amsterdam, the Netherlands (F.I.M., N.A.M.G., R.J.v.G., T.F.v.H., V.H., H.R.B., P.W.K., N.v.E.).ORCID 0000-0002-8358-2426 Vahram HovsepjanDepartment of Vascular Medicine, Amsterdam UMC Location University of Amsterdam, the Netherlands (F.I.M., N.A.M.G., R.J.v.G., T.F.v.H., V.H., H.R.B., P.W.K., N.v.E.).ORCID 0009-0001-2317-6645 Hanneke W M van LaarhovenDepartment of Medical Oncology, Amsterdam UMC Location Vrije Universiteit Amsterdam, the Netherlands (F.I.M., H.W.M.v.L., M. Labots).ORCID 0000-0003-1274-5643 Geert A CirkelDepartment of Internal Medicine, Meander Medical Ctr, Amersfoort, the Netherlands (G.A.C.).ORCID 0009-0007-8712-9825 Filip Y F L de VosDepartment of Medical Oncology, University Medical Ctr Utrecht, the Netherlands (F.Y.F.L.d.V.).ORCID 0000-0002-9082-5991 Laurens V BeerepootDepartment of Internal Medicine and Medical Oncology, Elisabeth-Tweesteden Hospital, Tilburg, the Netherlands (L.V.B.).ORCID 0000-0002-3040-4626 Judith de Vos-GeelenDepartment of Medical Oncology, GROW, Maastricht University Medical Centre, the Netherlands (J.d.V.-G.).ORCID 0000-0003-2578-1766 Mariette LabotsDepartment of Medical Oncology, Amsterdam UMC Location Vrije Universiteit Amsterdam, the Netherlands (F.I.M., H.W.M.v.L., M. Labots).ORCID 0000-0002-7095-1771 Paul HambergDepartment of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands (P.H.).ORCID 0000-0002-8223-0250 Annelie J E VulinkDepartment of Internal Medicine, Reinier de Graaf Hospital, Delft, the Netherlands (A.J.E.V.).ORCID 0009-0004-3426-8918 Aeilko H ZwindermanDepartment of Clinical Epidemiology, Biostatistics & Bioinformatics, Amsterdam University Medical Centre, the Netherlands (A.H.Z., B.F.).ORCID 0000-0003-0361-3139 Debbie G J RobbrechtDepartment of Medical Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands (D.G.J.R., M.J.A.d.J.).ORCID 0000-0003-2490-9991 Maja J A de JongeDepartment of Medical Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands (D.G.J.R., M.J.A.d.J.).
Harry R BüllerDepartment of Vascular Medicine, Amsterdam UMC Location University of Amsterdam, the Netherlands (F.I.M., N.A.M.G., R.J.v.G., T.F.v.H., V.H., H.R.B., P.W.K., N.v.E.).ORCID 0009-0000-4547-0901 Pieter W KamphuisenDepartment of Vascular Medicine, Amsterdam UMC Location University of Amsterdam, the Netherlands (F.I.M., N.A.M.G., R.J.v.G., T.F.v.H., V.H., H.R.B., P.W.K., N.v.E.).ORCID 0000-0002-6263-0177 Bart FerwerdaDepartment of Clinical Epidemiology, Biostatistics & Bioinformatics, Amsterdam University Medical Centre, the Netherlands (A.H.Z., B.F.).ORCID 0000-0002-7050-5931 Nick van EsDepartment of Vascular Medicine, Amsterdam UMC Location University of Amsterdam, the Netherlands (F.I.M., N.A.M.G., R.J.v.G., T.F.v.H., V.H., H.R.B., P.W.K., N.v.E.).ORCID 0000-0001-5256-6346 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
backgroundInternational guidelines suggest prophylactic anticoagulation for patients with cancer at high risk of venous thromboembolism (VTE). Here, we evaluated whether tumor whole-genome sequencing data may improve the selection of high-risk patients.
methodsIn a pan-cancer cohort of 3087 patients, associations of candidate clinical predictors, the germline extended 297-single nucleotide polymorphism polygenic risk score, tumor mutational characteristics, and somatic tumor mutations with VTE were estimated by calculating hazard ratios (HRs).
resultsDuring 12-month follow-up, 237 (7.7%) developed VTE. The germline extended 297-single nucleotide polymorphism score was associated with VTE (HR per point increase, 2.11 [95% CI, 1.45-3.06]), as well as the total number of somatic structural variants (HR per 1000 increase, 1.21 [95% CI, 1.07-1.37]) and 129 somatic mutations (unadjusted
conclusionsThese data indicate that tumor whole-genome sequencing may improve VTE prediction by clinical risk scores. Validation studies to confirm these findings are needed.
Indexed as
NeoplasmsVenous ThromboembolismWhole Genome SequencingAgedFemaleGenetic Risk ScoreGerm-Line MutationHumansMaleMiddle AgedMutationNeoplasm MetastasisPolymorphism, Single Nucleotideanticoagulantsgerm cellshumansmutationneoplasms
Identifiers
PMID41958384
PMCPMC13263043
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390